• 2025-05-16  view:272 times
    On May 16, 2025, Qingdao Baheal Pharma Co., Ltd, a subsidiary of Baheal Pharma under Baheal Medical (301015.SZ), held a relocation ceremony to celebrate its Phase III construction project. Mr. Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, Mr. Hao Yu, Vice President of Baheal Pharma Group's Campus Operation, Ms. Zheng Aiju, General Manager of Qingdao Baheal Pharma, and other leaders and guests, as well as colleagues of Qingdao Baheal Pharma, were present at the ceremony to witness this important moment together.
  • 2025-02-28  view:624 times
    On February 22, 2025, the "China Intracranial Metastases Consortium" (CLAIM) held its founding meeting and the first Xuanwu Intracranial Metastases Forum in Beijing. The event brought together nearly 170 experts and scholars from 108 hospitals, spanning oncology, radiotherapy, neurosurgery, pathology, and imaging departments, to discuss multidisciplinary approaches to treating intracranial metastases, intending to enhance patient survival.
  • 2025-02-13  view:223 times
    February 13, 2025 - Qingdao Baheal Pharma Co., Ltd. (hereinafter referred to as "Baheal Medical," 301015.SZ), a leading pharmaceutical industrialization platform, has announced a new commercial collaboration with Shanghai Roche Pharmaceuticals Ltd. ("Roche Pharmaceuticals China").
  • 2024-12-02  view:7 times
    Recently, renowned global growth consulting firm Frost & Sullivan (Sullivan) officially published the “2024 Blue Book on Current Status and Trends of the Conjugated Drugs Industry”. This report provides a comprehensive analysis of the industry, examining technical pathways, innovation models, development pipelines, and investment trends. It also offers insightful projections on future directions and potential opportunities within the sector. Thanks to their remarkable technological innovations and breakthroughs in the conjugated drugs field, two companies invested in by Baheal Pharma Group—Radiopharma and Rabpharma—have been highlighted as exemplary case studies in the Blue Book.
  • 2024-11-26  view:237 times
    On November 25, 2024, BrioHealth Solutions, Inc., a wholly-owned BrioHealth's U.S. subsidiary, announced its independently developed fully magnetic levitation left ventricular assist device, BrioVAD®, had successful completed the first patient enrollment of the INNOVATE clinical trial at Emory University Hospital.
Back to Top